Want to see CLRB full AI Analyst Report?
Dexamethasone, Rituximab, Iopofosine I 131, Cyclophosphamate, Clr 131
Waldenstrom Macroglobulinaemia, Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinaemia Refractory, Waldenstrom Macroglobulinemia With Nodal Disease
Phase III
Not Yet Recruiting
Evaluation of Iopofosine I 131 vs. R-CD in WM Patients
Jul 30, 2026
―
Clr 131
High-Grade Glioma
Phase I
Active Not Recruiting
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
Oct 28, 2022
―
Clr 131
Osteosarcoma, Neuroblastoma, Rhabdomyosarcoma, Pediatric Solid Tumor, Ewing Sarcoma, Dipg, Pediatric Lymphoma, Pediatric Brain Tumor
Phase I
Active Not Recruiting
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
Mar 20, 2018
―
Iopofosine I 131 Single Dose, Iopofosine I 131 Multiple Dose, Iopofosine I 131 Fractionated Dose
Multiple Myeloma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia, Central Nervous System Lymphoma
Phase II
Active Not Recruiting
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Oct 28, 2016
―
Dexamethasone, I-131-Clr1404
Multiple Myeloma
Phase I
Completed
Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
Oct 22, 2014
―
I-124-Clr1404
Glioblastoma
Phase II
Terminated
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Jul 08, 2013
―
Nov-205
Hepatitis C
Phase II
Completed
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
Jan 26, 2010
―
Carboplatin, Paclitaxel, Nov-002
Non Small Cell Lung Cancer
Phase III
Completed
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Jun 29, 2006
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Cellectar Biosciences (CLRB) have in its pipeline
CLRB is currently developing the following drugs: Dexamethasone, Rituximab, Iopofosine I 131, Cyclophosphamate, Clr 131, Iopofosine I 131, Clr 125, Clr 131. These drug candidates are in various stages of clinical development as the company works toward FDA approval.